OTC · Drug Manufacturers - Specialty & Generic

Invion Limited (IVIXF) Stock

$0.04 +0.00% OTC: IVIXF Healthcare

Invion Limited, an Australian biopharmaceutical firm currently in the clinical development phase, is dedicated to pioneering light-activated therapies for a diverse range of cancers. Its leading therapeutic candidate, IVX-PDT, functions as a photosensitizer agent aimed at treating not only skin cancers but also various solid tumors, such as those found in the lung, prostate, ovaries, and in cases of mesothelioma.

Valuation

MetricValue
Price$0.04
Market Cap$4.03M
P/E Ratio-0.31
P/B Ratio0.61
P/S Ratio0.00
EPS (TTM)$-0.08
52-Week High$0.04
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-150.48%
ROA-129.83%
ROCE-118.28%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.11
Current Ratio0.14

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.0M$2.0M$3.0M$2.0M$0
Operating Profit$-1.0M$-2.0M$-1.0M$-4.0M$-3.0M
Net Profit$-1.0M$-2.0M$-1.0M$-6.0M$-6.0M
EPS$-0.02$-0.03$-0.02$-0.06$-0.08
Op Margin-67.5%-70.5%-40.2%-153.7%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$4.0M$14.0M$13.0M$15.0M$6.0M
Total Liabilities$1.0M$0$0$1.0M$1.0M
Cash$1.0M$6.0M$3.0M$1.0M$1.0M
Borrowings$0$0$0$0$0

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$0$-1.0M$-1.0M$-2.0M$-2.0M
Investing Cash Flow$0$-10.0M$-3.0M$-1.0M$0
Financing Cash Flow$0$-1.0M$0$0$1.0M
Net Cash Flow$0$5.0M$-3.0M$-2.0M$0
Free Cash Flow$0$-6.0M$-3.0M$-3.0M$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-0.96
FCF Yield-58.40%
Quick Ratio0.14
Interest Coverage-54.42
Return 1Y0.00%
Return 3Y-91.82%
Return 5Y-96.39%

Ownership

Insiders Held46.66%
Institutions Held0.00%
Institutions Float Held0.00%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACUSAcusphere, Inc. $0.00 — 0.00 $49 0.00%
AQSZFAequus Pharmaceuticals Inc. $0.00 — -1.52 $159161 0.00%
BLFEBioLife Sciences Inc. $0.00 — 0.00 $156683 0.00%
CBDLCBD Life Sciences Inc. $0.00 — -29.85 $375394 0.00%
DVLPGolden Developing Solutions, Inc. $0.00 — 0.00 $1413 0.00%

About Invion Limited

Invion Limited, an Australian biopharmaceutical firm currently in the clinical development phase, is dedicated to pioneering light-activated therapies for a diverse range of cancers. Its leading therapeutic candidate, IVX-PDT, functions as a photosensitizer agent aimed at treating not only skin cancers but also various solid tumors, such as those found in the lung, prostate, ovaries, and in cases of mesothelioma. The company engages in strategic collaborations to further its research and development efforts. It holds an R&D agreement with the Hudson Institute of Medical Research, partnering on several projects related to the Photosoft technology for cancer treatment. Additionally, Invion has established a research pact with the Peter MacCallum Cancer Centre to carry out pre-clinical and in-vitro studies focusing on its IVX-PDT photodynamic therapy for ano-genital cancers, including penile and anal forms. Established in 2000, Invion Limited is based in Melbourne, Australia.

Invion Limited is headquartered in AU.

Invion Limited (IVIXF) stock trades at $0.04 with a market capitalization of $4.03M. The stock is valued at a price-to-earnings (P/E) ratio of -0.31, price-to-book of 0.61, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.04, and currently trades at its 52-week high.

On profitability, Invion Limited generates a return on equity (ROE) of -150.48%, return on capital employed of -118.28%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.inviongroup.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides